BiotechTube
Home/Pipeline/COM902 (anti-TIGIT)

COM902 (anti-TIGIT)

Advanced solid tumors

Phase 1Active

Key Facts

Indication
Advanced solid tumors
Phase
Phase 1
Status
Active
Company
Compugen

About Compugen

Compugen is transforming the pathway to immuno-oncology therapeutics through its unique 'From Code to Cure®' approach. Its flexible-loop Unigen™ platform integrates AI/ML innovation with biological data to discover novel targets and develop first-in-class drugs for cancer patients refractory to current treatments. The company has validated its platform through multiple partnerships with pharmaceutical companies and is advancing a pipeline of clinical-stage programs targeting novel pathways in immuno-oncology.

View full company profile

Therapeutic Areas

OncologyImmuno-oncology

Other Advanced solid tumors Drugs

DrugCompanyPhase
SHR-1701Jiangsu Hengrui MedicinePhase 1
BAY 1895344BayerPhase 1
HS-10342Hansoh PharmaPhase 1/2
ANKTIVA® + M-ceNKImmunityBioPhase 1
DFTX-101Definium TherapeuticsPhase 1/2
REC-617Recursion PharmaceuticalsPhase 1/2
ZW220ZymeworksPreclinical
NX-1607Nurix TherapeuticsPhase 1a
IMA402 (TCR Bispecific)ImmaticsPhase 1
IMA403 (TCR Bispecific)ImmaticsPre-clinical
BCA101Bicara TherapeuticsPhase 1
AN4005Adlai NortyePreclinical